Capricor Therapeutics: A High-Stakes Gamble on a Single Clinical Trial

The shares of biotech firm Capricor Therapeutics have become a pure speculative instrument, with their fate entirely dependent on the outcome of one pivotal clinical study. Investor sentiment is caught between the hope for life-saving data and the palpable fear of a complete loss, a tension recently amplified by a prominent short-seller’s public bet against the company.

Amid the uncertainty, Capricor does possess some defensive strengths. The company’s current financial position offers a critical buffer. With approximately $98.6 million in liquid assets, management states its operational runway extends through the final quarter of 2026. This capital is essential to advance not only its lead candidate but also other research Read more...